Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Node‐Positive HR+, HER2− Breast Cancer (Nodal pCR and the Rate of ALND): A Systematic Review and Meta‐Analysis.

MLA

Vasigh, Mahtab, et al. “Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Node‐Positive HR+, HER2− Breast Cancer (Nodal PCR and the Rate of ALND): A Systematic Review and Meta‐Analysis.” Breast Journal, vol. 2024, Aug. 2024, pp. 1–12. EBSCOhost, https://doi.org/10.1155/2024/8866756.

APA

Vasigh, M., Karoobi, M., Williams, A. D., Abreha, F. M., Bleicher, R. J., Yazd, S. M. M., Shamsi, T., Omranipour, R., Elahi, A., Farhat, D., Habibi, M., & Sahgal, P. (2024). Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Node‐Positive HR+, HER2− Breast Cancer (Nodal pCR and the Rate of ALND): A Systematic Review and Meta‐Analysis. Breast Journal, 2024, 1–12. https://doi.org/10.1155/2024/8866756

Chicago

Vasigh, Mahtab, Mohammadreza Karoobi, Austin D. Williams, Fasika Molla Abreha, Richard J. Bleicher, Seyed Mostafa Meshkati Yazd, Tahereh Shamsi, et al. 2024. “Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Node‐Positive HR+, HER2− Breast Cancer (Nodal PCR and the Rate of ALND): A Systematic Review and Meta‐Analysis.” Breast Journal 2024 (August): 1–12. doi:10.1155/2024/8866756.